NCT04735978 2026-02-27
Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours
Replimune Inc.
Phase 1 Active not recruiting
Replimune Inc.
Inimmune Corporation
BicycleTx Limited
Vaxiion Therapeutics
Mirati Therapeutics Inc.